Crecimiento, regeneración y radiosensibilidad de callos de caña de azúcar (Saccharum spp. híbrido var. “SP 70-1284”) tratados con radiación gamma fuente 60Co

Calluses in growth of sugar cane, variety “SP 70-1284”, were radiated with a source of 60Co. The studied doses were between 10 and 80 Gy. The affectation of the Gamma radiation source 60Co in the growth of the callus and the regeneration of plants was evaluated. The results indicated that the dose that diminished the growth of callus in a value under 50% was the one of 30 Gy, and also the dose that diminished the regenerative capacity of the callus below to the 50% of the population was the one of 30 Gy. The results showed that for this variety of sugar cane doses superior to 30Gy of Gamma radiations jeopardizes the growth and the later regeneration of the callus. Its application is recommended to induce genetic variability in the variety of sugar cane “SP 70-1284”, as well as in programs of genetic improvement by mutations, in susceptible varieties of the sugar cane red blight (Puccinia melanocephala Syd) using calluses in growth.Key words: callus, hybrid, in vitro, improvement, rust, Saccharum sp, variabilityCallos en crecimiento de caña de azúcar de la variedad “SP 70-1284”, fueron irradiados con una fuente de 60Co. Las dosis estudiadas fueron entre 10 y 80 Gy. Se evaluó la afectación de la radiación Gamma fuente 60Co en el crecimiento del callo y la regeneración de plantas. Los resultados indicaron que la dosis que disminuyó el crecimiento de callo en un valor por debajo del 50% fue la de 30 Gy, así mismo se encontró que la dosis que disminuyó la capacidad regenerativa del callo menor al 50% de la población fue la de 30 Gy. Los resultados mostraron que para esta variedad de caña de azúcar dosis superiores a 30 Gy de radiaciones Gamma comprometen el crecimiento y la posterior regeneración del callo. Se recomienda su aplicación para inducir variabilidad genética en la variedad de caña de azúcar “SP 70-1284”, así como en programas de mejora genética por mutaciones, en variedades susceptibles a roya de la caña de azúcar (Puccinia melanocephala Syd) empleando callos en crecimiento.Palabras clave: callo, híbrido, in vitro, mejoramiento, roya, Saccharum sp., variabilida

Guidelines for the use and interpretation of assays for monitoring autophagy (4th edition)1.

In 2008, we published the first set of guidelines for standardizing research in autophagy. Since then, this topic has received increasing attention, and many scientists have entered the field. Our knowledge base and relevant new technologies have also been expanding. Thus, it is important to formulate on a regular basis updated guidelines for monitoring autophagy in different organisms. Despite numerous reviews, there continues to be confusion regarding acceptable methods to evaluate autophagy, especially in multicellular eukaryotes. Here, we present a set of guidelines for investigators to select and interpret methods to examine autophagy and related processes, and for reviewers to provide realistic and reasonable critiques of reports that are focused on these processes. These guidelines are not meant to be a dogmatic set of rules, because the appropriateness of any assay largely depends on the question being asked and the system being used. Moreover, no individual assay is perfect for every situation, calling for the use of multiple techniques to properly monitor autophagy in each experimental setting. Finally, several core components of the autophagy machinery have been implicated in distinct autophagic processes (canonical and noncanonical autophagy), implying that genetic approaches to block autophagy should rely on targeting two or more autophagy-related genes that ideally participate in distinct steps of the pathway. Along similar lines, because multiple proteins involved in autophagy also regulate other cellular pathways including apoptosis, not all of them can be used as a specific marker for bona fide autophagic responses. Here, we critically discuss current methods of assessing autophagy and the information they can, or cannot, provide. Our ultimate goal is to encourage intellectual and technical innovation in the field

Actas de las V Jornadas ScienCity 2022. Fomento de la Cultura Científica, Tecnológica y de Innovación en Ciudades Inteligentes

ScienCity es una actividad que viene siendo continuada desde 2018 con el objetivo de dar a conocer los conocimientos y tecnologías emergentes siendo investigados en las universidades, informar de experiencias, servicios e iniciativas puestas ya en marcha por instituciones y empresas, llegar hasta decisores políticos que podrían crear sinergias, incentivar la creación de ideas y posibilidades de desarrollo conjuntas, implicar y provocar la participación ciudadana, así como gestar una red internacional multidisciplinar de investigadores que garantice la continuación de futuras ediciones. En 2022 se recibieron un total de 48 trabajos repartidos en 25 ponencias y 24 pósteres pertenecientes a 98 autores de 14 instituciones distintas de España, Portugal, Polonia y Países Bajos.Fundación Española para la Ciencia y la Tecnología-Ministerio de Ciencia, Innovación y Universidades; Consejería de la Presidencia, Administración Pública e Interior de la Junta de Andalucía; Estrategia de Política de Investigación y Transferencia de la Universidad de Huelva; Cátedra de Innovación Social de Aguas de Huelva; Cátedra de la Provincia; Grupo de investigación TEP-192 de Control y Robótica; Centro de Investigación en Tecnología, Energía y Sostenibilidad (CITES

Bound states in the continuum in a fluxonium qutrit

11 pags., 8 figs., 1 tab.Heavy fluxonium at zero external flux has a long-lived state when coupled capacitively to any other system. We analyze it by projecting all the fluxonium-relevant operators into the qutrit subspace, as this long-lived configuration corresponds to the second excited fluxonium level. This state becomes a bound state in the continuum (BIC) when the coupling occurs to an extended system supporting a continuum of modes. In the case without noise, we find BIC lifetimes T_1 that can be much larger than seconds when the fluxonium is coupled to a superconducting waveguide, while typical device frequencies are on the order of gigahertz. We have performed a detailed study of the different sources of decoherence in a realistic experiment, finding that upwards transitions caused by a finite temperature in the waveguide and decay induced by 1/f flux noise are the most dangerous ones. Even in their presence, BIC decay times could reach the range of T_1~10^{¿1} ms, while preparation times are of the order of 10^2 ns.This work is supported by the European Union’s Horizon 2020 FET-Open project AVaQus Grant No. 899561, by Comunidad de Madrid Sinérgicos 2020 project NanoQuCo-CM (Ref. Y2020/TCS-6545), and CSI

Growing, regeneration and radiosensibility of sugarcane callus (Saccharum spp. hybrid var. “SP 70-1284”) treated with gamma radiation source 60Co.

Calluses in growth of sugar cane, variety “SP 70-1284”, were radiated with a source of 60Co. The studied doses were between 10 and 80 Gy. The affectation of the Gamma radiation source 60Co in the growth of the callus and the regeneration of plants was evaluated. The results indicated that the dose that diminished the growth of callus in a value under 50% was the one of 30 Gy, and also the dose that diminished the regenerative capacity of the callus below to the 50% of the population was the one of 30 Gy. The results showed that for this variety of sugar cane doses superior to 30Gy of Gamma radiations jeopardizes the growth and the later regeneration of the callus. Its application is recommended to induce genetic variability in the variety of sugar cane “SP 70-1284”, as well as in programs of genetic improvement by mutations, in susceptible varieties of the sugar cane red blight (Puccinia melanocephala Syd) using calluses in growth. Key words: callus, hybrid, in vitro, improvement, rust, Saccharum sp, variabilit

Contemporary use of cefazolin for MSSA infective endocarditis: analysis of a national prospective cohort

Objectives: This study aimed to assess the real use of cefazolin for methicillin-susceptible Staphylococcus aureus (MSSA) infective endocarditis (IE) in the Spanish National Endocarditis Database (GAMES) and to compare it with antistaphylococcal penicillin (ASP). Methods: Prospective cohort study with retrospective analysis of a cohort of MSSA IE treated with cloxacillin and/or cefazolin. Outcomes assessed were relapse; intra-hospital, overall, and endocarditis-related mortality; and adverse events. Risk of renal toxicity with each treatment was evaluated separately. Results: We included 631 IE episodes caused by MSSA treated with cloxacillin and/or cefazolin. Antibiotic treatment was cloxacillin, cefazolin, or both in 537 (85%), 57 (9%), and 37 (6%) episodes, respectively. Patients treated with cefazolin had significantly higher rates of comorbidities (median Charlson Index 7, P <0.01) and previous renal failure (57.9%, P <0.01). Patients treated with cloxacillin presented higher rates of septic shock (25%, P = 0.033) and new-onset or worsening renal failure (47.3%, P = 0.024) with significantly higher rates of in-hospital mortality (38.5%, P = 0.017). One-year IE-related mortality and rate of relapses were similar between treatment groups. None of the treatments were identified as risk or protective factors. Conclusion: Our results suggest that cefazolin is a valuable option for the treatment of MSSA IE, without differences in 1-year mortality or relapses compared with cloxacillin, and might be considered equally effective

Long-term safety and efficacy of patisiran for hereditary transthyretin-mediated amyloidosis with polyneuropathy: 12-month results of an open-label extension study

© 2020 Elsevier Ltd. All rights reserved.Background: Hereditary transthyretin-mediated amyloidosis is a rare, inherited, progressive disease caused by mutations in the transthyretin (TTR) gene. We assessed the safety and efficacy of long-term treatment with patisiran, an RNA interference therapeutic that inhibits TTR production, in patients with hereditary transthyretin-mediated amyloidosis with polyneuropathy. Methods: This multicentre, open-label extension (OLE) trial enrolled patients at 43 hospitals or clinical centres in 19 countries as of Sept 24, 2018. Patients were eligible if they had completed the phase 3 APOLLO or phase 2 OLE parent studies and tolerated the study drug. Eligible patients from APOLLO (patisiran and placebo groups) and the phase 2 OLE (patisiran group) studies enrolled in this global OLE trial and received patisiran 0·3 mg/kg by intravenous infusion every 3 weeks with plans to continue to do so for up to 5 years. Efficacy assessments included measures of polyneuropathy (modified Neuropathy Impairment Score +7 [mNIS+7]), quality of life, autonomic symptoms, nutritional status, disability, ambulation status, motor function, and cardiac stress, with analysis by study groups (APOLLO-placebo, APOLLO-patisiran, phase 2 OLE patisiran) based on allocation in the parent trial. The global OLE is ongoing with no new enrolment, and current findings are based on the interim analysis of the patients who had completed 12-month efficacy assessments as of the data cutoff. Safety analyses included all patients who received one or more dose of patisiran up to the data cutoff. This study is registered with ClinicalTrials.gov, NCT02510261. Findings: Between July 13, 2015, and Aug 21, 2017, of 212 eligible patients, 211 were enrolled: 137 patients from the APOLLO-patisiran group, 49 from the APOLLO-placebo group, and 25 from the phase 2 OLE patisiran group. At the data cutoff on Sept 24, 2018, 126 (92%) of 137 patients from the APOLLO-patisiran group, 38 (78%) of 49 from the APOLLO-placebo group, and 25 (100%) of 25 from the phase 2 OLE patisiran group had completed 12-month assessments. At 12 months, improvements in mNIS+7 with patisiran were sustained from parent study baseline with treatment in the global OLE (APOLLO-patisiran mean change -4·0, 95 % CI -7·7 to -0·3; phase 2 OLE patisiran -4·7, -11·9 to 2·4). Mean mNIS+7 score improved from global OLE enrolment in the APOLLO-placebo group (mean change from global OLE enrolment -1·4, 95% CI -6·2 to 3·5). Overall, 204 (97%) of 211 patients reported adverse events, 82 (39%) reported serious adverse events, and there were 23 (11%) deaths. Serious adverse events were more frequent in the APOLLO-placebo group (28 [57%] of 49) than in the APOLLO-patisiran (48 [35%] of 137) or phase 2 OLE patisiran (six [24%] of 25) groups. The most common treatment-related adverse event was mild or moderate infusion-related reactions. The frequency of deaths in the global OLE was higher in the APOLLO-placebo group (13 [27%] of 49), who had a higher disease burden than the APOLLO-patisiran (ten [7%] of 137) and phase 2 OLE patisiran (0 of 25) groups. Interpretation: In this interim 12-month analysis of the ongoing global OLE study, patisiran appeared to maintain efficacy with an acceptable safety profile in patients with hereditary transthyretin-mediated amyloidosis with polyneuropathy. Continued long-term follow-up will be important for the overall assessment of safety and efficacy with patisiran.info:eu-repo/semantics/publishedVersio